非小细胞肺癌的靶向治疗

肺癌的发病率和死亡率在全球恶性肿瘤中居首位。其中,非小细胞肺癌（NSCLC）占80%~85%。绝大多数NSCLC在临床确诊时正处于复发或转移性的晚期阶段,化疗是这部分人群的主要治疗手段。但是,作为标准一线治疗的含铂两药联合化疗方案已进入平台期,无进展生存期（PFS）为4~6个月,总生存期（OS）仅为8~10个月。近年来,靶向药物的临床应用让人们看到了跨越这一平台的希望和曙光,靶向治疗作为一支生力军正逐渐登上非小细胞肺癌综合治疗的历史舞台。

Target therapy in advanced non-small cell lung cancer

The incidence and mortality of lung cancer ranks first in all kinds of malignant tumor around the world, in which non-small cell lung cancer accounts for 80% ～ 85%. The vast majority of NSCLC cases are identified when they are in the recurrent or metastatic advanced stage and chemotheraphy is their main cure method but the two-drug combined chemotherapy protocal has been in the plateau, progression-free survival is 4～6 months and overall survival is 8～10 months. In recent years, the clinical application of targeting drugs and target therapy has drawn much attention and been put into practice gradually.